Selective Cannabinoid Receptor Type 2 (CB2) Agonists: Optimization of a Series of Purines Leading to the Identification of a Clinical Candidate for the Treatment of Osteoarthritic Pain-Reference-Cited by-同舟云学术

Selective Cannabinoid Receptor Type 2 (CB2) Agonists: Optimization of a Series of Purines Leading to the Identification of a Clinical Candidate for the Treatment of Osteoarthritic Pain

Published:2013-07-03 Issue:14 Volume:56 Page:5722-5733
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Hollinshead Sean P.¹,Tidwell Michael W.¹,Palmer John¹,Guidetti Rossella²,Sanderson Adam²,Johnson Michael P.¹,Chambers Mark G.¹,Oskins Jennifer¹,Stratford Robert¹,Astles Peter C.²

Affiliation:

1. Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States

2. Lilly Research Center, A Division of Eli Lilly and Company, Erl Wood Manor, Sunningdale Road, Windlesham, Surrey GU20 6PH, U.K.

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm400305d

Reference53 articles.

1. Structure of a cannabinoid receptor and functional expression of the cloned cDNA

2. Molecular characterization of a peripheral receptor for cannabinoids